Navigation Links
Lexicon's IBS Drug Candidate, LX1033, Successfully Completes Phase 1 Clinical Trial
Date:7/28/2011

ic or commercial value of its drug candidates, that may cause Lexicon's actual results to be materially different from any future results expressed or implied by such forward-looking statements.  Unless specifically indicated otherwise, results reported as trends were not statistically significant. Information identifying such important factors is contained under "Risk Factors" in Lexicon's annual report on Form 10-K for the year ended December 31, 2010, as filed with the Securities and Exchange Commission.  Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Polaris Group to Highlight Clinical Development Plans for Phase 3-Ready Candidate, ADI-PEG 20, During Symposium in Taiwan
2. Cardioxyl Pharmaceuticals Presents Data On Its Clinical Candidate, CXL-1020, at the 60th Annual American College of Cardiology Scientific Session
3. Cardioxyl Pharmaceuticals Initiates Dose-Defining Phase IIa Study of Its Lead Candidate, CXL-1020, in Heart Failure Patients
4. Arcion Therapeutics Topical Gel Candidate, ARC-4558, Demonstrates Significant Pain Reduction in Phase 2b Trial for Painful Diabetic Neuropathy (PDN)
5. Regado Biosciences, Inc. Introduces REG2, Its Second Product Candidate, at the American College of Cardiology Conference, 59th Annual Scientific Session, in Atlanta, Georgia on March 15, 2010
6. Orexigen(R) Therapeutics Schedules September 30, 2009 Teleconference and Webcast to Discuss Phase 2b Trial Results From Second Obesity Drug Candidate, Empatic(TM)
7. Proteolix, Inc. Drug Candidate, PR-957, Prevents Disease Progression in Rheumatoid Arthritis Models by Selective Inhibition of the Immunoproteasome
8. Arcion Therapeutics Topical Pain Candidate, ARC-4558, Significantly Reduces Pain Caused by Diabetic Neuropathy
9. NovaBay Pharmaceuticals Announces Lead Anti-infective Product Candidate, NVC-422, Shown to be Effective in Treating Topical Fungal Infection
10. Bionovo Announces Development Plans for Menopausal Hot Flash Drug Candidate, Menerba (MF101), Following FDA Meetings
11. Ardea Biosciences Presents Phase 2a Antiviral Activity Data for Lead HIV Candidate, RDEA806 at XVII International AIDS Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... , May 21, 2013 Kepner-Tregoe (KT), ... announced that 13-year veteran Chris Geraghty ... Geraghty,s experience includes more than 20 years serving ... with manufacturing organizations. He succeeds Ray ... as Kepner-Tregoe,s Chairman of the Board and CEO. ...
(Date:5/21/2013)... , May 21, 2013  IsoRay, Inc. (AMEX: ... that it has entered into an exclusive international distribution ... complete product line in Greece . ... seed brachytherapy and medical radioisotope applications for brain cancer, ... gynecologic ("gyn") cancer. IASIS Medical is ...
(Date:5/21/2013)... Inc. (OTC BB: VASO) (the "Company"), a diversified medical technology ... devices and in the domestic sale of diagnostic imaging products, ... President and CEO of Vasomedical, Inc. will present at the ... 2013 in New York City at ... is scheduled to begin at 9:30 a.m. EDT. ...
Breaking Medicine Technology:Kepner-Tregoe, Inc. Promotes Chris Geraghty to Chief Executive Officer 2Kepner-Tregoe, Inc. Promotes Chris Geraghty to Chief Executive Officer 3IsoRay Announces A New International Distributor For Greece 2IsoRay Announces A New International Distributor For Greece 3Vasomedical, Inc. To Present At The Second Annual Marcum LLP MicroCap Conference 2
... Nephros, Inc. (OTC Bulletin Board: NEPH ... products for therapeutic applications, infection control, and water purification, ... reverse split of its common stock will take effect ... 2011. Nephros common stock will be quoted on the ...
... The Florida Society of Pain Management Providers ( www.Flspmp.org ... use in the United States. Until now these statistics ...  Oxycodone dispensed in U.S. 2009 by state (per 100,000 ... FDA.Translation from grams to 15mg tablets for comparison purposes ...
Cached Medicine Technology:Nephros Announces Completion of Reverse Stock Split 2Nephros Announces Completion of Reverse Stock Split 3Nephros Announces Completion of Reverse Stock Split 4Florida Pain Clinic Society: 3.7 Billion Oxycodone Tablets Dispensed in U.S. 2
(Date:5/21/2013)... 2013 According to a May 13, 2013 ... of Botox,” Botox injections have become the most ... 2002 (Go to goo.gl/8iYbD). Although it is mostly associated with ... The injection makes facial wrinkles less visible by paralyzing facial ... about three months. This means that people who are conscious ...
(Date:5/21/2013)... 2013 Phoseon Technology will present their ... 20th Annual IMI European Ink Jet Conference (June ... Phoseon continues to invest in product development to enable ... UV LED curing in printing applications. Phoseon currently ... market offering both air cooled and water cooled solutions ...
(Date:5/21/2013)... 2013 MedMar Healing Center announces ... Second Harvest Food Bank. Twenty-eight businesses, including MedMar Healing Center, ... food drive. The goal is to raise food to help ... facing their families in recent years. , “We like ... those in need,” explains Douglas Chloupek of MedMar Healing Center. ...
(Date:5/21/2013)... thrombospondin-1 and prosaposin, play in discouraging cancer metastasis, ... acid fragment of prosaposin that significantly reduces metastatic ... lung cancer. The findings suggest that a prosaposin-based ... of cancers. , The study team, led ... Vivek Mittal, PhD, at Weill Cornell Medical College ...
(Date:5/21/2013)... The Brazilian funding agency for scientific and technological research ... of So Paulo, announced an investment estimated in US$ ... Centers (RIDCs) for a period of up to eleven ... and 7. , Funding for the 17 RIDCs ... funding faculty, technicians, support personnel, and infrastructure). Host institutions ...
Breaking Medicine News(10 mins):Health News:Botox – Is the World’s Most Popular Cosmetic Procedure Safe? 2Health News:San Jose Cannabis Club Helps Feed Hungry Children with Second Harvest Food Bank 2Health News:Changing cancer's environment to halt its spread 2Health News:Changing cancer's environment to halt its spread 3Health News:Research at the cutting edge of knowledge 2
... fix for depression. Even if you are under medical care ... ,The December issue of Mayo Clinic Women's HealthSource offers five ... the risk of recurrence. ,1. Keep active. ... most days has been shown to improve mood. Long-term regular ...
... form of food poison. Then, fame came as a ... the 'miracle poison' and used for an increasing number ... of Mayo Clinic Health Letter covers how this drug ... ,Botulinum toxin blocks communication between nerves and muscles. ...
... drugs causing jaw problems have you wondering: Should you stop ... been reports of partial death of a jawbone (osteonecrosis) related ... to the December issue of Mayo Clinic Health Letter. ... — a disease that causes bones to become brittle and ...
... University of Rochester, Low doses of the drug mifepristone ... //and greatly improves the quality of life in women. ... of the journal, Obstetrics and Gynecology. ,Leiomyoma, ... of all women aged 35 to 49. The non-cancerous ...
... by the Department of Radiology at the University of ... the accuracy of diagnosing meniscal tears. ... there is one MR image with an abnormal finding. ... of 174 patients who had knee MR exams then ...
... one more reason why teenage years are perceived as ... the Pandora's Box has opened. //Such teens are prone ... no'vice' contemporaries, a recent insight indicates. ,The Canadian ... abuse tendencies among 15- to 19-year-olds, drawing on the ...
Cached Medicine News:Health News:Five Self-Care Strategies For Depression 2Health News:Mifepristone Reliable For Treating Uterine Fibroids 2Health News:Mifepristone Reliable For Treating Uterine Fibroids 3
DePuy 2 Bone Cement is a unique fast-set digital cement that is the excellent choice for small joint procedures such as the patella, glenoid or other extremity joints....
... Palacos® Bone Cement has clinically proven ... cemented arthroplasty. Palacos® is now available ... an antibiotic loaded bone cement cleared ... of a two-stage revision after infection ...
... System for Two-Dimensional Mapping of the ... uniquely merges two sophisticated measurement techniques, ... flowmetry, to a new kind of ... of the retinal micro-circulation., ,Using an ...
... block tear drainage through the canaliculus, synthetic absorbable ... symptoms:, Indicated for use in the treatment ... components of various ocular surface diseases, May be ... related complications and to enhance the retention of ...
Medicine Products: